Loading...

Humacyte, Inc.

HUMAW•NASDAQ
Healthcare
Biotechnology
$0.40
$-0.01(-2.44%)

Humacyte, Inc. (HUMAW) Stock Overview

Explore Humacyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.7/100

Key Financials

Market Cap320.8M
P/E Ratio-3.59
EPS (TTM)$-3.16
ROE2.86%
Fundamental Analysis

AI Price Forecasts

1 Week$0.65
1 Month$-0.02
3 Months$1.16
1 Year Target$1.17

HUMAW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Humacyte, Inc. (HUMAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.17.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.59 and a market capitalization of 320.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for HUMAWStats details for HUMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for HUMAWAnalyst Recommendations details for HUMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

CEO

Laura E. Niklason

Employees

218

Headquarters

2525 East North Carolina Highway 54, Durham, DE

Founded

1970

Frequently Asked Questions

;